Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
